Skip to content

BCBS Alabama

Does BCBS Alabama cover Wegovy for Liver Disease (MASH)?

Yes. BCBS Alabama covers Wegovy for liver disease (MASH) with prior authorization. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Liver Disease (MASH) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Noncirrhotic MASH with moderate-to-advanced fibrosis (F2-F3)

All of:

  • Adult patient (≥ 18 years)
  • Diagnosis of noncirrhotic MASH (formerly NASH)
  • Fibrosis stage F2 or F3 confirmed by non-invasive testing or biopsy
  • No cirrhosis

Plus any one of:

  • FIB-4 score indicating moderate/high risk (< 1.30 low risk; 1.30–2.67 indeterminate; > 2.67 high risk) with confirmatory testing as needed
  • VCTE/FibroScan elastography confirming F2-F3 fibrosis
  • MRE confirming F2-F3 fibrosis
  • ELF test result indicating significant fibrosis
  • Liver biopsy confirming MASH with F2-F3 fibrosis

Documentation to bring

  • Diagnosis of noncirrhotic MASH (formerly NASH/MASLD)
  • Confirmation of fibrosis stage F2 or F3 via non-invasive testing (FIB-4, ELF, VCTE/FibroScan, or MRE) or liver biopsy
  • FIB-4 as primary risk stratification with secondary confirmatory elastography or ELF if FIB-4 is indeterminate
  • Confirmation of absence of cirrhosis

Not covered when

  • Cirrhotic MASH is excluded (FDA indication limited to noncirrhotic MASH)
  • Concomitant use with other semaglutide-containing products not recommended
  • Concomitant use with any other GLP-1 receptor agonist not recommended
  • Pregnancy

Policy note: FDA indication for MASH is limited to Wegovy subcutaneous injection (not the tablet formulation listed separately). Fibrosis stage F2-F3 required per both FDA label and the NASH trial (NCT04822181) referenced in the document. The document outlines a two-step non-invasive testing approach: Step 1 FIB-4 (low risk < 1.30, indeterminate 1.30–2.67, high risk > 2.67; for patients > 65 years, higher cutoff > 2.0 for rule-in), Step 2 ELF and/or elastography (VCTE) with specific cutpoints referenced (ELF < 7.7 low risk, 7.7–9.8 intermediate, ≥ 9.8 high risk; VCTE < 8 kPa low risk, 8–12 kPa indeterminate, > 12 kPa high risk/advanced fibrosis). MRE also noted as an option. Lookback periods for testing are not explicitly specified in the PA criteria section of this document. Alcohol abstinence recommended in advanced fibrosis but no specific gram limits stated as PA criteria. This is a Program Summary document; specific PA approval criteria thresholds may be in a separate criteria document.

Policy effective April 20, 2026 · verified June 2, 2026 · source: Albp Weight Management Paql Prog Sum · View policy document (PDF)

Open on its own page →

Questions people ask
Does BCBS Alabama cover Wegovy?
Yes. BCBS Alabama covers Wegovy for liver disease (MASH) with prior authorization. Other policy requirements and your plan's benefits also apply.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Alabama: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: Alabama Medicaid, BCBS Arizona, BCBS Arkansas, BCBS Louisiana, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota, BCBS Nebraska

All insurance plans · All medications

Summary of BCBS Alabama's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.